SubsidieMeestersInnovative, minimally invasive device to support the natural movement of the heart in heart failure patients
Syntach CS is an innovative implantable device that restores natural heart movement in patients with left ventricular heart failure, enhancing cardiac function through synchronized support.
Projectdetails
Introduction
Syntach CS is a groundbreaking, life-saving device for long-term cardiac support that restores the natural function of the heart’s mitral plane movement in patients suffering from left ventricular heart failure.
Technology Overview
The technology is based on recent findings of the physiological movement of the intact heart, which pumps with a scooping, longitudinal movement of the mitral valve.
Heart Failure Impact
In heart failure, this movement is impaired, and the heart is unable to pump enough blood to meet the metabolic needs of the body.
Functionality
Syntach CS works in synchronization with the heart, supports the cardiac movements, and reestablishes a natural, healthy movement.
Implantation Procedure
It is fully implantable in a minimally invasive procedure. Heart movement support is enabled thanks to a mitral anchor ring connected to a drive unit implanted in the lower apex region of the heart, from which a pulsatile movement is transferred to the mitral plane.
Monitoring and Maintenance
The system is recharged and monitored wirelessly, with no elements protruding through the skin.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.500.000 |
| Totale projectbegroting | € 25.695.814 |
Tijdlijn
| Startdatum | 1-9-2022 |
| Einddatum | 31-3-2027 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- SYNTACH ABpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A new cardioprotective drug for acute treatment of myocardial infarctionResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Clear, scalable and scientific framework to measure terrestrial biodiversity3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value. | EIC Accelerator | € 2.252.714 | 2024 | Details |
Novel and Scalable microbial products for REgenerative agricultureN-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data SecurityQuside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors. | EIC Accelerator | € 2.499.999 | 2024 | Details |
A new cardioprotective drug for acute treatment of myocardial infarction
ResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies.
Clear, scalable and scientific framework to measure terrestrial biodiversity
3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value.
Novel and Scalable microbial products for REgenerative agriculture
N-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency.
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data Security
Quside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Novel microsensing platform for remote patient monitoringThe FORESEE project aims to advance implantable microstimulators for remote monitoring of chronic heart failure, enhancing patient care and market access for 10.5 million potential users. | EIC Transition | € 2.499.051 | 2023 | Details |
SPARK - Subcutaneous Pump and Advanced Remote KitRT Cardiac Systems ontwikkelt een innovatief percutaan mechanisch circulatieondersteuningsapparaat en een subcutane sensor om patiënten met gevorderd hartfalen beter te ondersteunen tijdens noodsituaties en ingrepen. | MIT R&D Samenwerking | € 199.138 | 2023 | Details |
SPARK - Subcutaneous Pump and Advanced Remote KitHet project ontwikkelt een innovatief hartondersteuningssysteem met een subcutane sensor voor betere behandeling van gevorderd hartfalen. | MIT R&D Samenwerking | € 199.138 | 2023 | Details |
Novel microsensing platform for remote patient monitoring
The FORESEE project aims to advance implantable microstimulators for remote monitoring of chronic heart failure, enhancing patient care and market access for 10.5 million potential users.
SPARK - Subcutaneous Pump and Advanced Remote Kit
RT Cardiac Systems ontwikkelt een innovatief percutaan mechanisch circulatieondersteuningsapparaat en een subcutane sensor om patiënten met gevorderd hartfalen beter te ondersteunen tijdens noodsituaties en ingrepen.
SPARK - Subcutaneous Pump and Advanced Remote Kit
Het project ontwikkelt een innovatief hartondersteuningssysteem met een subcutane sensor voor betere behandeling van gevorderd hartfalen.